Although equities have performed pretty well in the past three years, many somewhat speculative and unprofitable stocks have struggled as investors have turned their attention away from such corporations. That's the case with Editas Medicine (NASDAQ: EDIT), a clinical-stage gene editing-focused biotech company.

However, many analysts on Wall Street have high hopes for the stock. Editas Medicine's average price target of $15.64 implies an upside of about 55% over its stock price of $10.06 (as of writing). Can the company hit that goal within the next year? Let's find out.

Continue reading

Source Fool.com